Skip to content

Pharminent

cropped-ChatGPT-Image-May-26-2026-09_44_59-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Other
  • Seaport and Hemab target $180m IPOs as biotech listings accumulate
  • Other

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Pharmaceutical Technology

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaceutical Technology

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Boehringer/Zealand dual-acting drug causes 16.6% weight loss
Next: Novartis shares fall as Entresto sales weaken

Related Stories

  • Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026
  • Other

225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator

pharminent May 18, 2026
  • Other

Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies

pharminent May 18, 2026

You May Have Missed

  • M&A / Deals

Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss

pharminent May 27, 2026
  • Commercial

Kardigan targets IPO to support cardiology pipeline progression

pharminent May 27, 2026
  • Regulatory

FDA delays verdict on AZ breast cancer drug

pharminent May 27, 2026
  • Clinical Data

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

pharminent May 26, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.